20 November 2026
I’ve just published a new article on LinkedIn about AI in drug discovery: what is hype, what is now backed by clinical data, why foundation-model companies are moving into biotech, and why the real bottleneck has never been the algorithm but the data.

Image generated using AI
In short: the change is real. Computationally designed drugs such as zasocitinib and rentosertib have reached Phase III and FDA review, AI labs like Anthropic, OpenAI and Isomorphic Labs are moving into biotech directly, and AI agents are starting to run experiments in the wet lab. But AI-discovered molecules still fail in Phase II as often as traditional ones, because picking the right biology for the right patients is, fundamentally, a data problem.
Take home message: a model is only as good as the data behind it. The winners will be whoever controls the best data loop: generating high-quality experimental data, feeding it to models and testing their predictions in the lab and the clinic. And people are still needed: scientists who frame the right questions, generate trustworthy data and judge whether a prediction makes biological sense.
👉 Read the original article on LinkedIn
For convenience, here it is reproduced in full.
Every few months, AI is about to revolutionise drug discovery. Today the headlines are louder than ever, and for the first time they come with clinical data, regulatory filings and billion-dollar deals. So is this finally the moment, or another hype cycle?
My personal view: the change is real. But the limiting factor has never really been the algorithm. It has been, and still is, the data.
It doesn’t matter how good a model is; it can only learn what its data contains. In drug discovery, the data that matters most is scarce, fragmented and mostly locked inside companies.
The signal is clear. The most valuable assets aren’t the models, which are increasingly a commodity. They are high-quality, well-annotated, decision-relevant data, plus the closed loop between model and wet lab. This links back to my previous post on data products: no trusted data, no trusted AI.
Companies like Insilico Medicine, BenevolentAI, Exscientia and Recursion have claimed AI-discovered compounds for years. The record is now long enough to judge:
The data so far is nuanced. A BCG analysis published in Drug Discovery Today (Jayatunga et al., 2024) found AI-discovered molecules reached Phase I success rates of 80–90%, versus a 40–65% historical average. In Phase II, however, they were around 40%, similar to traditional drugs. AI seems to help make better molecules, but it doesn’t yet solve the hardest problem: picking the right biology for the right patients. That is, fundamentally, a data problem.
According to industry trackers, more than 100 AI-enabled assets have entered clinical trials, and as of mid-2026, none has received full FDA approval yet. That may be about to change.
This is the part that feels different. Foundation-model companies are no longer only selling tools to pharma. They are moving into the work itself:
The tools themselves are also becoming products. In November 2026 Google DeepMind launched Cheminformatics Skills for Antigravity, its Gemini-based agent platform. The LLM orchestrates the workflow and reasons, while deterministic tools built on RDKit and connected to ChEMBL and PubChem do the chemistry. In a lung cancer demo starting from crizotinib and its macrocyclic successor lorlatinib, the agent searched papers and patents, curated 568 relevant compounds, ran matched molecular pair analysis, built and validated potency models, and proposed new macrocycles with synthesis routes. DeepMind says this took about an hour, versus several days for a typical single iteration. Two caveats: that is the company’s own figure, not an independent benchmark, and none of the molecules has been made or tested yet.
DeepMind itself calls them “testable hypotheses, not finished drugs.” Nor is the idea new; academic agents such as ChemCrow (Bran et al., 2024) showed similar tool-using workflows earlier. What is new is the usability. The questions that matter now are total expert time, including review and correction, and traceability: can you follow each recommendation back to the calculation, the record and the paper, and does the tool keep measured data apart from predictions?
Most of AI’s impact in science so far has been computational: analysing data, making predictions, designing molecules. But an AI can design a promising molecule in minutes, while testing it still takes weeks or months of human effort. That gap is where data is generated, and it is the real bottleneck.
This is starting to change. A paper recently published in Nature (Wu et al., 2026) introduces AutoDNA, an automated lab where LLM-powered agents plan and run molecular biology experiments with little human intervention. A planner agent coordinates specialist agents that search the literature, check reagents, write protocols, generate code and operate more than 20 types of instruments. In one case study, the system optimised an enzymatic DNA synthesis reaction to 97.8% yield, comparable to expert-optimised results. In another, it detected a KRAS mutation in a colorectal cancer sample and designed primers to confirm it. One run involved 11,382 instrument operations over 200 hours. The agents also capped reaction tubes to prevent evaporation without being asked, the kind of tacit lab knowledge that rarely makes it into written protocols.
Connecting AI to instruments is the other half of the problem. Each manufacturer has its own programming interface, so today every autonomous lab is a custom engineering project. In August 2026 Anthropic released a research preview of the Model Hardware Standard (MHS), developed with HHMI Janelia: a shared, model-agnostic specification for how AI agents operate physical devices such as microscopes, liquid handlers and robotic arms. Partners include Genentech, Carnegie Mellon, the Baker lab at the University of Washington, Tecan, QIAGEN, Danaher and Automata. Early results include serial-dilution dose-response experiments running about three times faster at Carnegie Mellon and a proof-of-concept automated protein assay at Genentech. Zou compares this kind of standard to USB ports for the lab. Anthropic is also clear about the limits: Claude’s physical reasoning still needs expert oversight. For example, Genentech scientists had to guide it to treat foaming in protein samples as a physical problem, not a software bug.
The limits matter as much as the results. Humans still chose the tasks, prepared reagents, replenished supplies and cleared waste. Of 14 hardware errors, six needed a person. One run needed 84 refills of a single type of pipette tip. Automation is still limited to fairly standard assays. As James Zou notes in his commentary (Zou, 2026), the next step is to integrate computational and experimental agents into one closed-loop workflow. Whoever achieves that will own the most valuable thing in AI drug discovery: a fast, reliable engine for generating trustworthy data.
We have seen both sides of this movie.
AlphaFold was real. It changed structural biology so profoundly that it earned a Nobel Prize in 2024. Yet even AlphaFold did not translate directly into new drugs, because knowing a protein’s structure is only one piece of the puzzle.
IBM Watson Health was the opposite: enormous promises about transforming medicine, followed by its sale in 2022. It is a cautionary tale about technology arriving before the data, workflows and clinical integration were ready.
What’s different now? Three things:
I think we will see more of it. The pattern resembles other industries where tech entered verticals: first you sell tools, then you build platforms, then you buy the domain expertise and assets you can’t build fast enough. For AI labs, acquiring a biotech means three things: proprietary data, wet-lab feedback loops, and clinical credibility. For biotechs, it means access to frontier models and capital.
But acquisitions alone won’t win. The winners will be whoever controls the best data loop: generating high-quality experimental data, feeding it to models, and testing their predictions in the lab and the clinic.
AI in drug discovery is no longer only hype. It is becoming real, unevenly and more slowly than the headlines suggest. The first approvals of computationally designed drugs may arrive in 2027. Development timelines are shrinking, and AI is reaching parts of R&D that used to be out of reach.
But the old truth holds: a model is only as good as the data behind it. And people are still needed: scientists who frame the right questions, generate trustworthy data and judge whether a prediction makes biological sense.
Which do you think will win: the AI companies moving into biotech, or the pharma companies that own the data?
This article was written with the help of AI and was originally published on LinkedIn.